UiPath, Inc. (PATH) Stock Price & How to Invest

UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation (RPA) with AI-powered capabilities including agentic automation, process orchestration, intelligent document processing, and governance tooling. Its core product, the UiPath Platform, enables AI agents, software robots, and human workers to collaborate in coordinated workflows across industries including financial services, healthcare, manufacturing, retail, and the public sector. The company makes money primarily through subscription and cloud software licenses, which generate high gross margins in the 83-85 percent range, supplemented by professional services revenue. ARR, the annualized value of active subscription contracts, is its primary business-health metric and stood at $1.853 billion as of January 31, 2026.

UiPath was founded in 2005 in Bucharest, Romania by Daniel Dines and Marius Tarca, originally as a software outsourcing firm before pivoting to RPA. It relocated its headquarters to New York City and went public on the NYSE in April 2021 in one of the largest US software IPOs of that era. Dines, who serves as Founder and Chief Executive Officer, led the company through a period of rapid growth followed by a strategic reset that included executive changes and a renewed focus on operational efficiency. Chief Operating Officer and CFO Ashim Gupta has been credited with driving the cost discipline that produced the company's first full-year GAAP operating profit in fiscal 2026. The company employs approximately 4,000 people globally.

The central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. Competition from Automation Anywhere, Blue Prism, and emerging agentic AI startups intensifies pricing pressure and increases customer acquisition costs. UiPath's revenue growth has been inconsistent historically, and approximately 24 percent of its outstanding shares are sold short, reflecting meaningful market skepticism about whether the agentic pivot will translate into durable ARR acceleration. Insider selling, including by founder Daniel Dines, has also weighed on investor sentiment.

16 analysts publish price targets on PATH, averaging $13.25 against a $12.76 price as of August 2026, or +3.8%. The published targets run from $10.98 to $17.00, a moderate spread, and the ratings split 3 buy, 16 hold, 1 sell. Over the last six months there has been 1 raise and 10 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PATH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on UiPath, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Agentic Automation as the Next Growth Layer. UiPath is repositioning itself from an RPA vendor into what it calls a global leader in agentic automation, offering tools including Agent Builder, Agentic Orchestration, and UiPath Maestro for process intelligence. The most optimistic published target, $17.00, assumes this works close to its best case.

The case against. The central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. The most pessimistic target, $10.98, is roughly what PATH is worth if this bites instead.

Read the full bull and bear case on PATH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see UiPath, Inc.'s investor relations page or your broker.

• Revenue (FY2026, ended Jan 31, 2026): ~$1.61 billion
• Revenue Growth (FY2026 YoY): ~13%
• ARR (as of Jan 31, 2026): ~$1.85 billion
• GAAP Gross Margin (FY2026): ~83%
• Free Cash Flow (FY2026): ~$372 million
• Market Capitalization: ~$5.3 billion
• Trailing P/E Ratio: ~17x
• Forward P/E Ratio: ~12x
• EV/EBITDA: ~32x
• Cash and Marketable Securities: ~$1.69 billion

UiPath's trailing P/E of roughly 17x sits well below the broader US software sector average of approximately 26x, reflecting the market's uncertainty about whether agentic AI tailwinds will translate into sustained double-digit ARR growth. The company's strong gross margin profile of 83 percent and $372 million in FY2026 free cash flow indicate a fundamentally healthy software business, but the stock has declined significantly from its post-IPO highs as growth decelerated and competition intensified. The forward P/E of roughly 12x implies the market is pricing in limited earnings growth, creating a potential valuation gap if the re-acceleration seen in recent quarters proves durable.

If you want PATH exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to PATH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PATH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BOTZ, ROBO, ARKK), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PATH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PATH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

UiPath today is an enterprise automation platform in active transition, with ARR of $1.853 billion growing 11 percent year-over-year and a freshly minted GAAP profit demonstrating real operating leverage, yet its stock trades at a trailing P/E of roughly 17x, well below the broader software sector average, because the market is discounting the risk that agentic AI from larger, better-capitalized rivals could structurally compress its growth ceiling. If you believe that enterprises will need a dedicated, governed orchestration layer to coordinate AI agents alongside existing RPA and that UiPath's installed base and Gartner Magic Quadrant leadership provide durable switching costs, the question becomes sizing and overlap with other automation or AI positions, not timing; the risk is that Microsoft Power Automate and native AI capabilities from cloud hyperscalers gradually absorb UiPath's use cases without UiPath capturing meaningful share of the newer agentic workloads.

Whether PATH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PATH a buy or a sell?, and where the stock could go from here in the PATH stock forecast.

For income investors, whether PATH pays a dividend and how the payout looks is covered in does PATH pay a dividend? And to weigh PATH against a peer, read the full side-by-side comparisons: PATH vs MSFT and PATH vs IT.